Shiv K. Singh

2.7k total citations
33 papers, 1.5k citations indexed

About

Shiv K. Singh is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Shiv K. Singh has authored 33 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Shiv K. Singh's work include Pancreatic and Hepatic Oncology Research (13 papers), Epigenetics and DNA Methylation (7 papers) and Glioma Diagnosis and Treatment (5 papers). Shiv K. Singh is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Epigenetics and DNA Methylation (7 papers) and Glioma Diagnosis and Treatment (5 papers). Shiv K. Singh collaborates with scholars based in Germany, United States and United Kingdom. Shiv K. Singh's co-authors include Lorenz C. Hofbauer, Harald Dobnig, Thomas M. Gress, Uday Kishore, Volker Ellenrieder, Albrecht Neeße, Elisabeth Heßmann, Lukas Klein, S Buchholz and Abhishek Shastri and has published in prestigious journals such as Journal of Biological Chemistry, Physiological Reviews and Gastroenterology.

In The Last Decade

Shiv K. Singh

31 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shiv K. Singh Germany 19 766 629 274 245 223 33 1.5k
Yumei Lai China 27 959 1.3× 595 0.9× 137 0.5× 280 1.1× 95 0.4× 57 1.8k
Adelheid Korb Germany 8 950 1.2× 482 0.8× 491 1.8× 198 0.8× 232 1.0× 9 2.0k
Tania Velletri Italy 12 953 1.2× 381 0.6× 147 0.5× 350 1.4× 92 0.4× 16 1.6k
Berno Dankbar Germany 18 842 1.1× 447 0.7× 177 0.6× 187 0.8× 109 0.5× 33 1.5k
Katarzyna Kozar Poland 17 811 1.1× 387 0.6× 193 0.7× 376 1.5× 103 0.5× 23 1.6k
Elizabeth Allan Australia 24 1.1k 1.5× 658 1.0× 178 0.6× 275 1.1× 146 0.7× 40 1.7k
Nabanita S. Datta United States 20 1.5k 1.9× 874 1.4× 103 0.4× 506 2.1× 215 1.0× 39 2.3k
Deshui Jia China 17 1.1k 1.4× 307 0.5× 147 0.5× 717 2.9× 159 0.7× 24 1.6k
Wen Ling United States 15 579 0.8× 589 0.9× 91 0.3× 113 0.5× 82 0.4× 45 1.2k
Sarah Hatsell United States 20 951 1.2× 469 0.7× 87 0.3× 152 0.6× 106 0.5× 32 1.5k

Countries citing papers authored by Shiv K. Singh

Since Specialization
Citations

This map shows the geographic impact of Shiv K. Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiv K. Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiv K. Singh more than expected).

Fields of papers citing papers by Shiv K. Singh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiv K. Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiv K. Singh. The network helps show where Shiv K. Singh may publish in the future.

Co-authorship network of co-authors of Shiv K. Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Shiv K. Singh. A scholar is included among the top collaborators of Shiv K. Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiv K. Singh. Shiv K. Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Küffer, Stefan, Lukas Klein, Christof Lenz, et al.. (2025). TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Science Advances. 11(27). eadu2339–eadu2339.
2.
Joseph, Ann Mary, et al.. (2024). Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma. Frontiers in Immunology. 15. 1323198–1323198. 13 indexed citations
3.
4.
Zhang, Zhe, Xin Wang, Feda H. Hamdan, et al.. (2023). NFATc1 Is a Central Mediator of EGFR-Induced ARID1A Chromatin Dissociation During Acinar Cell Reprogramming. Cellular and Molecular Gastroenterology and Hepatology. 15(5). 1219–1246. 3 indexed citations
5.
Rahman, Raza‐Ur, Christine S. Gibhardt, K Reutlinger, et al.. (2022). NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut. 71(12). 2561–2573. 46 indexed citations
6.
Espinet, Elisa, Lukas Klein, Ellen Puré, & Shiv K. Singh. (2022). Mechanisms of PDAC subtype heterogeneity and therapy response. Trends in cancer. 8(12). 1060–1071. 37 indexed citations
7.
Klein, Lukas, Florian Wegwitz, Elisa Espinet, et al.. (2022). Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. JCI Insight. 7(16). 5 indexed citations
8.
Zhang, Zhe, Silke Kaulfuß, Bernd Wollnik, et al.. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Cancers. 14(14). 3451–3451. 10 indexed citations
9.
Reutlinger, K, Jochen Gaedcke, Philipp Ströbel, et al.. (2021). Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Cells. 10(12). 3463–3463. 4 indexed citations
10.
Singh, Shiv K., et al.. (2021). The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Frontiers in Oncology. 11. 642603–642603. 29 indexed citations
11.
Shastri, Abhishek, Anthony G. Tsolaki, Hadida Yasmin, et al.. (2020). Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. Frontiers in Immunology. 11. 1402–1402. 226 indexed citations
12.
Murugaiah, Valarmathy, Ansar A. Pathan, Annapurna Nayak, et al.. (2019). Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma Multiforme patients. Immunobiology. 224(5). 625–631. 11 indexed citations
13.
Baumgart, Sandra, Jin‐San Zhang, Daniel D. Billadeau, et al.. (2016). GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Molecular Cancer Therapeutics. 15(3). 491–502. 37 indexed citations
14.
Singh, Shiv K., Roberto Fiorelli, Robert Kupp, et al.. (2016). Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway. Cell Reports. 16(4). 950–966. 49 indexed citations
15.
Singh, Shiv K. & Volker Ellenrieder. (2013). Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics. Gut. 62(9). 1364–1372. 21 indexed citations
16.
Baumgart, Sandra, Garima Singh, K Reutlinger, et al.. (2011). Restricted Heterochromatin Formation Links NFATc2 Repressor Activity With Growth Promotion in Pancreatic Cancer. Gastroenterology. 142(2). 388–398.e7. 73 indexed citations
17.
Singh, Shiv K., Sandra Baumgart, Garima Singh, et al.. (2011). Disruption of a Nuclear NFATc2 Protein Stabilization Loop Confers Breast and Pancreatic Cancer Growth Suppression by Zoledronic Acid. Journal of Biological Chemistry. 286(33). 28761–28771. 22 indexed citations
18.
Rachner, Tilman D., Martina Rauner, Claudia Goettsch, et al.. (2009). Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL‐induced apoptosis. Journal of Cellular Biochemistry. 108(1). 106–116. 33 indexed citations
19.
Rachner, Tilman D., Shiv K. Singh, Michael Schoppet, et al.. (2009). Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Letters. 287(1). 109–116. 51 indexed citations
20.
Muyal, Jai Prakash, Shiv K. Singh, & Heinz Fehrenbach. (2008). DNA-Microarray Technology: Comparison of Methodological Factors of Recent Technique Towards Gene Expression Profiling. Critical Reviews in Biotechnology. 28(4). 239–251. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yumei Lai Breakdown of academic impact, for papers by Adelheid Korb Breakdown of academic impact, for papers by Tania Velletri Breakdown of academic impact, for papers by Berno Dankbar Breakdown of academic impact, for papers by Katarzyna Kozar Breakdown of academic impact, for papers by Elizabeth Allan Breakdown of academic impact, for papers by Nabanita S. Datta Breakdown of academic impact, for papers by Deshui Jia Breakdown of academic impact, for papers by Wen Ling Breakdown of academic impact, for papers by Sarah Hatsell
Rankless by CCL
2026